The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > LATEST
LATEST
-
REGULATORY PMDA Chief Strenuously Delivering Info on Japan Regulations at Overseas Confabs
June 17, 2024
-
BUSINESS MSD Files Prevymis for Pediatric Use, Granules Form in Japan
June 17, 2024
-
BUSINESS Eisai CEO’s Son Promoted to Representative Officer & EVP
June 17, 2024
-
BUSINESS Eisai CEO’s Pay Tops 200 Million Yen: Securities Report
June 17, 2024
-
ORGANIZATION FPMAJ Hails 2024 Reform, but Frets No Mention of Scrapping Off-Year Cuts in Honebuto Draft
June 17, 2024
-
BUSINESS Bridion Generic Vials Hit Market in Droves at 32% of Originator Price
June 14, 2024
-
REGULATORY First Generics Joining NHI Price List in June Hits Record Low, Bridion is Only Target
June 14, 2024
-
REGULATORY MHLW Proposes Supply Info System for All Prescription Drugs, FY2027 Launch Eyed
June 14, 2024
-
ACADEMIA MHLW-Funded Study Group Designing New Care Delivery Model for Alzheimer’s
June 14, 2024
-
BUSINESS Choseido Contract Manufactured Cephem Antibiotics for 8 Firms
June 14, 2024
-
BUSINESS GSK to Discontinue Immediate-Release Versions of Paxil in Japan
June 14, 2024
-
REGULATORY SanBio’s Lead Cell Therapy Up for Review Again on June 19
June 14, 2024
-
BUSINESS Pfizer Has High Hopes for Elrexfio/Prevenar 20, Rich ADC Assets after Seagen Deal
June 13, 2024
-
REGULATORY Tezspire Braced for CEA Price Cut, AstraZeneca's Appeal Dismissed
June 13, 2024
-
REGULATORY LDP Members Urge Modification of Honebuto Draft to Push Rethink of Off-Year Drug Price Cuts
June 13, 2024
-
ACADEMIA Leukemia Drug Slows ALS Progression in Japan Clinical Trial
June 13, 2024
-
BUSINESS Lilly Set to Raise Profile as Only Eczema Player with Oral and Injectable Options
June 13, 2024
-
BUSINESS Astellas’ Gastric Cancer Drug Vyloy Now Available in Japan
June 13, 2024
-
BUSINESS Ono Completes Acquisition of Deciphera
June 13, 2024
-
BUSINESS En Route to 2030 Target, Shionogi to Carve Out New Biz in Areas with High Medical Needs
June 12, 2024
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…